BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based immunotherapy company developing novel T-cell therapies to treat individuals diagnosed with liquid and solid tumors. Their mission is to rapidly screen, identify, and validate TCR-based therapies for accelerated delivery to the clinic, aiming to give every cancer patient a chance for a cure. They focus on innovative platform technologies like TCXpress™ and NeoXPress™ to advance their pipeline of personalized cancer treatments.
Industries
Nr. of Employees
small (1-50)
BlueSphere Bio
350 Technology Drive, Suite 520, Pittsburgh, PA 15219
Products
Engineered TCR T-cell therapy program targeting blood-restricted antigens paired with allogeneic stem cell transplant
Pipeline of engineered T cell receptor therapies directed at blood-restricted antigens designed to be administered in conjunction with allogeneic CD34+ stem cell transplantation for hematologic malignancies.
Autologous engineered TCR T-cell program targeting NPM1-derived neoantigens
Autologous TCR-engineered T-cell program targeting neoantigens generated by mutant NPM1 in acute myeloid leukemia; lead candidate progressing through IND-enabling studies.
High-throughput TCR discovery platform (integrated capture, single-cell, and analysis)
Integrated discovery platform combining automated capture, single-cell sequencing/characterization and bioinformatics pipelines to identify antigen-specific TCRs for therapeutic development.
Engineered TCR T-cell therapy program targeting blood-restricted antigens paired with allogeneic stem cell transplant
Pipeline of engineered T cell receptor therapies directed at blood-restricted antigens designed to be administered in conjunction with allogeneic CD34+ stem cell transplantation for hematologic malignancies.
Autologous engineered TCR T-cell program targeting NPM1-derived neoantigens
Autologous TCR-engineered T-cell program targeting neoantigens generated by mutant NPM1 in acute myeloid leukemia; lead candidate progressing through IND-enabling studies.
High-throughput TCR discovery platform (integrated capture, single-cell, and analysis)
Integrated discovery platform combining automated capture, single-cell sequencing/characterization and bioinformatics pipelines to identify antigen-specific TCRs for therapeutic development.
Expertise Areas
- T cell receptor discovery and development
- T-cell engineering for autologous cell therapies
- Bispecific protein and antibody engineering
- Single-cell genomics and NGS workflows
Key Technologies
- Next-generation sequencing (NGS) and single-cell RNA-seq
- T cell receptor search and capture platforms
- Parallelized capture workflows and scalable analysis pipelines
- Lentiviral vector production and banking
News & Updates
BlueSphere Bio announced that Robert Keefe, Ph.D., Chief Development Officer, will present data at the SITC Annual Meeting.
BlueSphere Bio announced the appointment of Keir Loiacono, Esq. as CEO, bringing nearly 20 years of leadership experience in biopharma.
BlueSphere Bio demonstrated that their platforms significantly increase throughput, reduce costs, and shorten the timeline for identifying novel TCRs.
BlueSphere Bio announced their participation in the CAR-TCR Summit in Boston, MA.
BlueSphere Bio's CEO, Dr. David Apelian, will provide a corporate overview at the BIO International Convention.
Sawa Ito, M.D., Ph.D., will present data at the ASTCT + EBMT Scientific Retreat.
BlueSphere Bio announced that Robert Keefe, Ph.D., Chief Development Officer, will present data at the SITC Annual Meeting.
BlueSphere Bio announced the appointment of Keir Loiacono, Esq. as CEO, bringing nearly 20 years of leadership experience in biopharma.
BlueSphere Bio demonstrated that their platforms significantly increase throughput, reduce costs, and shorten the timeline for identifying novel TCRs.
BlueSphere Bio announced their participation in the CAR-TCR Summit in Boston, MA.
BlueSphere Bio's CEO, Dr. David Apelian, will provide a corporate overview at the BIO International Convention.
Sawa Ito, M.D., Ph.D., will present data at the ASTCT + EBMT Scientific Retreat.